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Abstract
Background Intra-articular (IA) injection of hyaluronic
acid (HA) into the hip joint appears to be safe and well
tolerated but only a small number of randomized clinical
trials in humans has been published. The objective of this
prospective study was to evaluate the efficacy and safety of
a single IA injection of high-molecular-weight (2800 kDa)
HA (Coxarthrum) for hip osteoarthritis.
Materials and methods All patients received a single IA
administration of 2.5 % sodium hyaluronate (75 mg/3 mL)
of high molecular weight. Fluoroscopy requires an iodized
contrast medium (iopamidol, 1 ml) which highlights the
capsule before administering HA. Patients were evaluated
before IA injection (T0), after 3 months, after 6 months
and after 1 year from injection. Results were evaluated by
the Brief Pain Inventory (BPI II), Harris Hip Score and a
visual analog scale of pain (pain VAS). All treated patients
were considered for statistical analysis.
Results Two hundred seven patients were included at T0.
The mean age was 67 years (range 46–81). Regarding BPI
severity score, changes in pain between T0 and the three
following visits were statistically highly significant
(p\ 0.001). Changes in pain score compared to the pre-
vious visit were statistically significant for the worst pain in
the second quarter post-intervention (p = 0.037) and for
mean pain in the second semester post-intervention
(p = 0.043) The evolution of the Harris Hip Score was
statistically highly significant (p\ 0.001) between T0 and
the following visits (T0 ? 3 months, T0 ? 6 months and
T0 ? 12 months); after a significant change between T0
and T0 ? 3 months, the score remained stable. The evo-
lution of the pain VAS showed a statistically highly sig-
nificant improvement (p\ 0.001) between T0 and
T0 ? 3 months; thereafter it remained stable from the first
quarter post-intervention. No serious adverse event was
noted; 12 cases (0.5 %) of pain associated with transient
synovitis are noteworthy.
Conclusion This study shows that a single IA injection of
Coxarthrum is effective from the third month and that the
results are stable or continue to improve up to 1 year.
Level of evidence IV.
Keywords Hip  Viscosupplementation  Hyaluronic acid
Introduction
Osteoarthritis has a very high prevalence globally. It is a
source of pain and deterioration of joint function, with
important socioeconomic consequences. The related pain is
poorly evaluated by doctors, who underestimate its inten-
sity when the pain is reported by the patient as being high,
and overestimate it when it is reported as being weak [1].
The incidence of hip arthritis is increasing with age and is
estimated at between 47.3 (95 % confidence interval [CI]
27.8–66.8) [1] and 88/100 000 patient-years (95 % CI
65–101) [2]. Hip pain is reported by 19.2 % (95 % CI
17.9–20.6) of people aged 65 years and older. Less than
half (48 %) of the symptomatic respondents had unilateral
problems affecting one hip or knee joint only [1].
Optimal management of osteoarthritis requires a com-
bination of non-pharmacological and pharmacological
modalities. Among the latter are injections of intra-articu-
lar (IA) hyaluronic acid (HA), first isolated in 1934 by Karl
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Meyer in the vitreous humor; the first human clinical use of
IA HA in the treatment of knee arthritis was made in 1975,
and the first trials date back to 1980 [1]. HA is a
polysaccharide macromolecule, a glycosaminoglycan of
high molecular weight (MW) composed of repetitions of
disaccharides of glucuronic acid and N-acetylglucosamine;
it is a constituent of synovial fluid in normal and osteoar-
thritic joints and is synthesized by chondrocytes and syn-
oviocytes [2]. HA has complex biological properties that
could explain its analgesic effects (anti-inflammatory by
inhibiting the formation and release of prostaglandin,
immunomodulatory in situ), irrespective of its mechanical
action on the joint fluid. The concentration of HA in an
arthritic joint has been found to decrease to 50–33 % of
normal levels, and includes a reduction in molecular size.
Molecular interaction has also been observed, with a con-
sequent decrease in elasticity and viscosity of the synovial
fluid [3].
HA may be useful in patients with knee or hip
osteoarthritis. The symptomatic benefit is delayed in
comparison with that of intra-articular injections of corti-
costeroids, but it is prolonged. The IA injections of HA are
widely used and recommended in existing guidelines as a
useful therapeutic modality to treat patients with knee
osteoarthritis; there is less experimental evidence of effi-
cacy for hip arthritis than for knee arthritis [4].
IA injection of HA into the hip joint appears to be safe
and well tolerated [5] but only a small number of ran-
domized clinical trials in humans has been published [6–9].
Data from a meta-analysis in knee arthritis suggested
that the heterogeneity between trials might be due to the
higher MW products having greater efficacy. Indeed, HA
preparations may broadly be classified according to their
MW and formulation type: solutions of low MW
(500–1200 kDa), solutions of high MW (6000 kDa), cross-
linked HA and solutions of non-animal stabilized HA
(NASHA) [10–12].
As a consequence, the objective of this prospective
study was to evaluate the efficacy and safety of IA injection
of a single dose of high MW (2800 kDa) HA (75 mg/
3 mL) (Coxarthrum, LCA Pharmaceutical, Chartres,
France) for hip osteoarthritis.
Materials and methods
The study protocol was approved according to the modal-
ities planned by Ethical Committee. We conducted a sin-
gle-center, prospective, unblinded study. After baseline
(T0), patients were to be reviewed at 3, 6 and 12 months.
Inclusion criteria were age more than 40 years, mono- or
bilateral hip arthritis with X-ray proof of at least partially
preserved joint space (Kellgren–Lawrence stage 2–3 [10]),
good or full joint mobility, and hip disease persisting for at
least 3 months. Patients were excluded from the study
where they had severe arthritis for which it was no longer
possible to recognize radiographic joint space (Kellgren–
Lawrence stage 4), had inflammatory, autoimmune and
septic disease (rheumatoid arthritis, connective tissue dis-
ease, osteomyelitis), or had surgical indication for hip
arthroplasty. All patients received a single injection of a
single administration of 2.5 % sodium hyaluronate (75 mg/
3 mL) of high MW (2800 kDa) (Coxarthrum). This is a
sterile, viscoelastic, transparent, homogeneous preparation
composed of purified HA, without any avian protein; it is
not cross-linked by a chemical agent, which limits as much
as possible the risks of allergic and cytotoxic reactions.
Injections were performed by fluoroscopic guidance. Flu-
oroscopy requires an iodized contrast medium (iopamidol,
1 ml) which highlights the capsule before administering
HA. Patients were evaluated before IA injection (T0), after
3 months, after 6 months and after 1 year from injection.
The first endpoint was the score on the Modified Brief Pain
Inventory (BPI II) comprising (1) a score of pain severity
(BPI severity score) rated between zero and 10 and mea-
suring the pain which the subjects felt before the present
visit (the worst pain, the lightest pain, the mean pain) and
the pain now, that is to say the pain felt during the visit; (2)
an impact score (BPI interference score) rated between
zero and 10, describing disturbances of social life (work,
sleep and mood); (3) an overall impact score adding the
previous score and four other items (activities in general,
ability to walk, relationships with others, the enjoyment of
life). Another criterion of evaluation was the Harris Hip
Score whose range is from zero to 100 with points dis-
tributed within four areas: ‘‘pain’’ domain, maximum 44
points; ‘‘function’’ domain, maximum 47 points; ‘‘range of
motion’’ domain, maximum 5 points; ‘‘no deformity’’
domain, maximum 4 points. Finally, a visual analog scale
(VAS) of pain (pain VAS), scored from zero to 10, also
allowed judging the effectiveness of IA HA.
All treated patients were considered for statistical anal-
ysis, which was performed in SAS software (version 9.2).
At each study time (T0, T0 ? 3 months, T0 ? 6 months
and T0 ? 12 months), mean, standard deviation and median
endpoints were calculated. For the same endpoint, compar-
isons were made at different study times using Student’s
t test for paired samples. Results were considered statisti-
cally significant for values of p\ 0.05.
Results
Two hundred seven patients were included at T0. One
hundred twenty-six were women (61 %) and eighty-one
were men (49 %). The mean age was 67 years (range
22 J Orthopaed Traumatol (2016) 17:21–26
123
46–81). Mean body mass index (kg/m2) was 22.8 (range
18.8–29.9). Radiological evaluation of osteoarthritis
showed a Kellgren–Lawrence stage 2 in 83 (40.1 %)
patients and a Kellgren–Lawrence stage 3 in 124 (59.9 %)
patients. The number of included patients who completed
the questionnaires in the various planned visits gradually
decreased over time; however, data from three-quarters of
patients were still available after 6 months, and data from
over half the patients after 1 year. The data of pain VAS
were less available than those of the BPI II questionnaires
and the Harris Hip Score (Table 1).
Regarding the BPI severity score, changes in pain
between T0 and the three following visits were statistically
highly significant (p\ 0.001). Changes in pain score
compared to the previous visit were statistically significant
for the worst pain in the second quarter post-intervention
(p = 0.037) and for mean pain in the second semester post-
intervention (p = 0.043) (Table 2). Changes in pain
severity (BPI severity score) are shown in Fig. 1. Note the
parallelism of the curves, although the intensity of the
worst pain is virtually unchanged from T0 ? 3 months
onwards.
The evolution of the BPI interference score, describing
disturbances of social life, measured between T0 and the
three following visits, was statistically highly significant
(p\ 0.001) for the three items describing disturbances of
social life (work, sleep and mood). The evolution of the
BPI interference score measured against the previous visit
was also highly significant (p\ 0.001) from the second
quarter post-intervention for sleep and for the second
semester post-intervention for mood. It was significant
(p\ 0.05) concerning professional activities for the second
semester post-intervention (Table 3).
The evolution of the BPI interference overall score
between T0 and the three following visits was statistically
highly significant (p\ 0.001). The evolution of the BPI
interference overall score measured against the previous
visit was statistically significant in the second quarter post-
intervention (p\ 0.01) and statistically highly significant
during the second semester post-intervention (p\ 0.001)
(Table 4).
The evolution of the Harris Hip Score was statistically
highly significant (p\ 0.001) between T0 and the fol-
lowing visits (T0 ? 3 months, T0 ? 6 months and
T0 ? 12 months); after a significant change between T0
and T0 ? 3 months, the score remained stable (Fig. 2).
Table 1 Number of patients completing the questionnaires at the various visits
No. of patients available at
T0 T0 ? 3 months T0 ? 6 months T0 ? 12 months
BPI II questionnaire (severity and interference) 207 207 150 121
Harris Hip Score 207 207 150 121
VAS of pain 165 176 128 104
Table 2 Evolution of patients’ pain (BPI II severity score)




T0 ? 3 months
Between T0 ? 3 months
and T0 ? 6 months
Between T0 ? 6 months and
T0 ? 12 months
Worst pain 6.03 (1.51) 4.78 (1.95)* 4.90 (2.16)*, 4.80 (2.00)*
Slightest pain 3.80 (1.92) 2.91 (1.68)* 2.52 (1.61)* 2.42 (1.43)*
Mean pain 4.93 (1.49) 3.78 (1.64)* 3.42 (1.68)* 3.22 (1.57)*,
Pain during visit 4.07 (2.04) 3.00 (1.94)* 2.73 (1.98)* 2.55 (1.63)*
* Statistically highly significant (p\ 0.001) compared with T0
 Statistically significant (p\ 0.05) compared with the previous visit
Fig. 1 Evolution of BPI Severity Score during follow-up
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As for the evolution of the Harris Hip Score, the evo-
lution of the pain VAS showed a statistically highly sig-
nificant improvement (p\ 0.001) between T0 and
T0 ? 3 months; thereafter it remained stable from the first
quarter post-intervention.
No serious adverse event was noted; 12 cases (0.5 %) of
pain associated with transient synovitis (during 24 h) are
noteworthy.
Discussion
To evaluate the efficacy and safety of a single IA of HA
(75 mg/3 mL) of high MW (2800 kDa) (Coxarthrum) for
hip osteoarthritis pain management, we included in our
study two hundred seven patients. In this unblinded
prospective study, changes in all outcome measures were
significantly in favor of a single IA injection, whether it
was the BPI severity score, the BPI interference score, the
Harris Hip Score or the pain VAS. This trend was very
clear from T0 ? 3 months; then the results remained
stable or continued to improve on all these criteria.
Only a small number of scientific papers containing
statistically significant results about hip IA injection of HA
are available in the literature despite the hip being the
second most common site of arthritis.
Conrozier and colleagues [11] retrospectively evaluated
a group of 56 patients with severe or moderate hip
osteoarthritis after one or two IA administrations of high
MW HA. At 90 days follow-up, 58.9 % of the patients
reported a benefit of the infiltration treatment.
A prospective double-blind study compared the effect of
high MW and low MW HA, together with a placebo. In this
study 59 patients were evaluated at time intervals of 1, 3
and 6 months after the first infiltration. Similarly to our
study, improvement of scores was noted at 1 month and
remained significant up to 6 months in both groups com-
pared to the placebo group (p\ 0.001). No significant
differences were observed between the results obtained in
the two study groups treated with the different HA mole-
cules [12].
Berg and Olsson [13] studied a group of 31 patients with
hip osteoarthritis at 2 weeks and 3 months follow-up after
a single administration of non-animal, stabilized HA
Table 3 Evolution of the BPI interference score describing disturbances of social life




T0 ? 3 months
Between T0 ? 3 months
and T0 ? 6 months
Between T0 ? 6 months
and T0 ? 12 months
Professional activities 4.44 (2.15) 3.42 (1.94)* 3.26 (2.45)* 2.59 (1.97)*,
Sleep 3.80 (2.23) 2.59 (1.76)* 2.01 (1.78)*,H 1.31 (1.17)*,H
Mood 4.11 (2.18) 3.14 (2.12)* 2.79 (2.45)* 1.83 (1.61)*,H
* Statistically highly significant (p\ 0.001) compared with T0
 Statistically significant (p\ 0.05) compared with previous visit
H Statistically highly significant (p\ 0.001) compared with previous time




T0 ? 3 months
Between T0 ? 3 months
and T0 ? 6 months
Between T0 ? 6 months
and T0 ? 12 months
Mean (±SD) 30.40 (13.65) 22.81 (11.92)* 19.83 (13.72)*, 14.17 (9.78)*,H
Median 30 20 20.5 10
* Statistically highly significant (p\ 0.001) compared with T0
 Statistically significant (p\ 0.01) compared with previous time
H Statistically highly significant (p\ 0.001) compared with previous visit
Fig. 2 Evolution of Harris Hip Score during follow-up
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(NASHA). Three months after administration, there was a
statistically significant 68 % improvement in symptoms
(p\ 0.007).
Colen and colleagues [5] evaluated the efficacy of hip
viscosupplementation by analysing the results of 16 trials
with a total of 509 patients, with evidence levels varying
from I to IV, and using various types of preparations.
Notwithstanding the relatively low level of evidence in the
trials, the authors concluded that viscosupplementation
may be an alternative therapy for treating coxarthrosis.
Intra-articular infiltration has proved to be safe and well-
tolerated therapy. However, the authors state the need for
trials on a larger number of people in order to avoid having
to consider HA infiltration in the hip as an extremely
selective choice that depends on the experience of the
operator. The same group of authors [14] reported that
51 % of the patients had not undergone surgery 3 years
after viscosupplementation, after evaluation of a group of
120 patients who were candidates for surgical treatment
with a total hip arthroplasty.
To overcome the problem of selectivity and operator-
dependent approach to hip viscosupplementation, a clear
identification of whether or not the patient is suitable for
HA infiltration treatment in the hip is mandatory. Although
studies of variability in the efficacy of HA infiltration
therapy in the hip compared to the gravity of the hip
arthritis have not yet been carried out, it can reasonably be
assumed, as reported by knee viscosupplementation stud-
ies, that the possibilities of efficacy and duration of the
beneficial effects of the treatment are inversely propor-
tional to the gravity of the disease [15]. For this reason
selection criteria for the candidate patient are vital to obtain
pain relief in cases of hip arthritis. These selection criteria
consist of hip pain for at least 3 weeks, X-ray proof of at
least partially-preserved joint space, and good or full joint
mobility. Hip viscosupplementation can be used as an
alternative to or in combination with drugs for pain control.
This type of approach to viscosupplementation therapy
does not correspond to the inclusion criteria reported in
Van den Bekerom and colleagues’ study [14]. Considering
hyaluronic acid as a pain therapy, using its beneficial
effects on cartilage due to both the pharmacological and
the physical properties of the molecule [16–18], then the
use of injection in cases of low or medium degrees of hip
arthritis is mandatory. For this reason, patient candidates
for hip arthroplasty were excluded for our study.
Recently, to clarify some aspects of viscosupplementa-
tion treatment, a review of the literature confirmed that IA
HA is an effective treatment for mild to moderate
osteoarthritis but it is not an alternative to surgery in
advanced cartilage degeneration [19].
Fluoroscopic guidance is one of the possible radiologi-
cal guidances when performing IA hip injection. Due to the
narrow IA space, performing a ‘‘blind’’ hip IA injection is
not recommended [20]. Ultrasound guidance does not need
contrast media and can also be repeated without causing
problems of radiation load for the patient or operator, but
exposure to radiation during fluoroscopy is minimal and
there is no difference in the speed of IA injection between
the two techniques when performed by experts. The choice
between ultrasound or fluoroscopy is based on the experi-
ence of the operator in using both methods [20]. However,
when IA injection is performed under fluoroscopy, the
amount of radiopaque contrast agent must be as low as
possible to avoid viscosupplement dilution [19].
In our experience, we observed 12 cases of pain asso-
ciated with transient synovitis after IA injection. As
reported in the literature [21–24], transient synovitis cor-
related with the reaction to a foreign body is a minor
complication with an incidence of between 5 and 10 %.
This adverse reaction normally resolves in 24–48 h fol-
lowing infiltration. without long-term clinical effects.
Further studies are needed on unresolved hip viscosup-
plementation issues including cost–effectiveness of ther-
apy, relation between molecular weight and effectiveness,
and how to best incorporate viscosupplementation into an
arthritis therapy algorithm. Our experience proved the
efficacy of IA HA injection for hip arthritis treatment.
A single dose of HA (75 mg/3 mL) of high MW
(2800 kDa) is proving to be safe and effective for pain
control in patients with hip arthritis (Kellgren–Lawrence
stages 2 and 3) before indications for hip arthroplasty. Vis-
cosupplementation is effective from the third month and the
results are stable or continue to improve up to 1 year.
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